Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 4A




Figure 4B




Figure 4C




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

P1 P2 P3 P4 P5

P6




Figure 10



tumor volume (cm3)
10
8
6
4
2
0
0 2 4 7 9 11 14 16 17 19 22 24 26 29 31 33
days after first treatment
---x--- DDW
—o— CDDP 3mg/kg (1/week)
—●— CBP501 40mg/kg (2/week)
—□— CBP 501 10mg/kg (2/week) + CDDP 3mg/kg (1/week)
—◆— CBP 501 40mg/kg (2/week) + CDDP 3mg/kg (1/week)

Figure 11




Figure 12




Figure 13




Figure 14




Figure 15

Overall survival in ICON enrolled patients in relation to baseline WBC counts

WBC <10000
Median OS Arm A: 19.0M (n=45), Arm B: 16.6M (n=49); HR: 0.58
WBC <9000
Median OS Arm A: 22.0M (n=41), Arm B: 17.0M (n=40); HR: 0.54
WBC <8000
Median OS Arm A: 22.0M (n=33), Arm B: 16.6M (n=33); HR: 0.41
P=0.0186*(statistically significant)
WBC <7000
Median OS Arm A: 22.0M (n=24), Arm B: 18.4M (n=26); HR: 0.46




Figure 16



Chemo alone
Percent survival
100
80
60
40
20
0
0
500
1000
Time
17M
14M
Chemo_<8000
Chemo_>8000
Paitent number 96
Hazard ratio 0.9
P value 0.8
Chemo+CBP50
Percent survival
100
80
60
40
20
0
0
500
1000
Time
22M
11M
Chemo+CBP501_<8000
Chemo+CBP501_>8000
Patient number 96
Pazard ratio 0.3
P value <0.0001

Figure 17



NET inducers+501
0.300
0.250
0.200
0.150
0.100
0.050
0.000
None
1nM PMA
3uM A23187
10uM A23187
100ng/ml LPS
1000ng/ml LPS
None
1uM 501

Figure 18




Figure 19A




Figure 19B





Figure 20



* P < 0.01 [p=0.0027

Figure 21A




Figure 21B




Figure 21C




Figure 22A




Figure 22B




Figure 23




Figure 24




Figure 25



Relative tumor volume change of BALB/c mice beared CT-26 colon carcinoma (CB-221)
relative tumor volume
141.00
121.00
101.00
81.00
61.00
41.00
21.00
1.00
1 3 5 7 9 11 13 15 17 19 21 23 25 27
days after first treatment
1.5% glu(100ul)iv×2<Day1>
5% glu(100ul)iv then 4h Saline(250)ip<Day2>
PBS(100ul)ip<Day3>
2.5% glu(100ul)iv×2<Day1>
5% glu(100ul)iv then 4h CDDP(5)ip<Day2>
PBS(100ul)ip<Day3>
3.5% glu(100ul)iv×2<Day1>
5% glu(100ul)iv then 4h Saline(250)ip<Day2>
anti-PD1 antibody(200ug)ip<Day3>
4. 5% glu(100ul)iv×2<Day1>
5% glu(100ul)iv then 4h CDDP(5)ip<Day2>
anti-PD1 antibody(200ug)ip<Day3>
5. CBP501(7.5)iv×2 <Day1>
CBP501(7.5)iv then 4h Saline(250)ip<Day2>
PBS(100ul)ip<Day3>
6. CBP501(7.5)iv×2 <Day1>
CBP501(7.5)iv then 4h CDDP(5)iv Saline(250)ip<Day2>
PBS(100ul)ip<Day3>
7. CBP501(7.5)iv×2 <Day1>
CBP501(7.5)iv then 4h CDDP(5)iv Saline(250)ip<Day2>
anti-PD1 antibody(200ug)ip<Day3>

Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31





Figure 32


Figure32
vehicle
CDDP
combo
PDI
CDDP+PDI
Combo+PDI
n.s.
Combo+PDI(n=3), other (n=4)
* P<0.05
** P<0.01